BioNTech paid $200 million to share in the development of an immunotherapy with potential advantages over a blockbuster Bristol Myers Squibb product from the same drug class. Now the German company and partner OncoC4 are reporting the clinical data that led to the deal.
In Phase 1/2 results,…
Source: medcitynews.com – Read more
The Digital Imperative: Why the Future of Surgery Will Be Built on Integrated Intelligence, Not More Devices
The future of surgery will be shaped less by what our tools can do than by how well our systems help humans think when it
